Serda Maciej, Kalinowski Danuta S, Rasko Nathalie, Potůčková Eliška, Mrozek-Wilczkiewicz Anna, Musiol Robert, Małecki Jan G, Sajewicz Mieczysław, Ratuszna Alicja, Muchowicz Angelika, Gołąb Jakub, Simůnek Tomáš, Richardson Des R, Polanski Jaroslaw
Institute of Chemistry, University of Silesia, Katowice, Silesia, Poland.
Department of Pathology and Bosch Institute, University of Sydney, Sydney, New South Wales, Australia.
PLoS One. 2014 Oct 16;9(10):e110291. doi: 10.1371/journal.pone.0110291. eCollection 2014.
Thiosemicarbazones (TSCs) are an interesting class of ligands that show a diverse range of biological activity, including anti-fungal, anti-viral and anti-cancer effects. Our previous studies have demonstrated the potent in vivo anti-tumor activity of novel TSCs and their ability to overcome resistance to clinically used chemotherapeutics. In the current study, 35 novel TSCs of 6 different classes were designed using a combination of retro-fragments that appear in other TSCs. Additionally, di-substitution at the terminal N4 atom, which was previously identified to be critical for potent anti-cancer activity, was preserved through the incorporation of an N4-based piperazine or morpholine ring. The anti-proliferative activity of the novel TSCs were examined in a variety of cancer and normal cell-types. In particular, compounds 1d and 3c demonstrated the greatest promise as anti-cancer agents with potent and selective anti-proliferative activity. Structure-activity relationship studies revealed that the chelators that utilized "soft" donor atoms, such as nitrogen and sulfur, resulted in potent anti-cancer activity. Indeed, the N,N,S donor atom set was crucial for the formation of redox active iron complexes that were able to mediate the oxidation of ascorbate. This further highlights the important role of reactive oxygen species generation in mediating potent anti-cancer activity. Significantly, this study identified the potent and selective anti-cancer activity of 1d and 3c that warrants further examination.
硫代氨基脲(TSCs)是一类有趣的配体,具有多种生物活性,包括抗真菌、抗病毒和抗癌作用。我们之前的研究已经证明了新型TSCs在体内具有强大的抗肿瘤活性,以及它们克服对临床使用的化疗药物耐药性的能力。在当前的研究中,利用其他TSCs中出现的逆片段组合设计了6种不同类别的35种新型TSCs。此外,通过引入基于N4的哌嗪或吗啉环,保留了先前确定对强大抗癌活性至关重要的末端N4原子处的二取代。在多种癌症和正常细胞类型中检测了新型TSCs 的抗增殖活性。特别是,化合物1d和3c作为具有强大且选择性抗增殖活性的抗癌剂显示出最大的潜力。构效关系研究表明,利用“软”供体原子(如氮和硫)的螯合剂具有强大的抗癌活性。事实上,N、N、S供体原子组合对于形成能够介导抗坏血酸氧化的氧化还原活性铁络合物至关重要。这进一步突出了活性氧生成在介导强大抗癌活性中的重要作用。值得注意的是,本研究确定了1d和3c具有强大且选择性的抗癌活性,值得进一步研究。